UY24805A1 - Peptidos y compuestos que se enlazan al receptor de la trombopoyetina - Google Patents

Peptidos y compuestos que se enlazan al receptor de la trombopoyetina

Info

Publication number
UY24805A1
UY24805A1 UY24805A UY24805A UY24805A1 UY 24805 A1 UY24805 A1 UY 24805A1 UY 24805 A UY24805 A UY 24805A UY 24805 A UY24805 A UY 24805A UY 24805 A1 UY24805 A1 UY 24805A1
Authority
UY
Uruguay
Prior art keywords
peptides
bind
compounds
receptor
thrombopoyetine
Prior art date
Application number
UY24805A
Other languages
English (en)
Spanish (es)
Inventor
William J Dower
Ronald Barrett
Steven Cwirla
Christian M Gates
Peter J Schatz
Palaniappan Balasubramanian
Peter Schatz
Christopher Wagstrom
Richard Hendren
Randolph Deprince
Surekha Podduturi
Qun Yin
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25071323&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY24805(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of UY24805A1 publication Critical patent/UY24805A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
UY24805A 1996-12-11 1997-12-10 Peptidos y compuestos que se enlazan al receptor de la trombopoyetina UY24805A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/764,640 US5869451A (en) 1995-06-07 1996-12-11 Peptides and compounds that bind to a receptor

Publications (1)

Publication Number Publication Date
UY24805A1 true UY24805A1 (es) 2000-12-29

Family

ID=25071323

Family Applications (1)

Application Number Title Priority Date Filing Date
UY24805A UY24805A1 (es) 1996-12-11 1997-12-10 Peptidos y compuestos que se enlazan al receptor de la trombopoyetina

Country Status (24)

Country Link
US (2) US5869451A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (3) EP0948539B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP4128225B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (3) KR100679576B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN100379760C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (2) AR010752A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE420893T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU725731B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BRPI9713914B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2274149C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO5080768A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69739219D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2321038T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP970683B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MA (1) MA26454A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PA (1) PA8442601A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (1) PE27599A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SV (1) SV1997000104A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TN (1) TNSN97201A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TR (2) TR200401638T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW515804B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UY (1) UY24805A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1998025965A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA9711045B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA001220B1 (ru) * 1995-06-07 2000-12-25 Глаксо Груп Лимитед Пептид или пептидомиметик, который связывается с рецептором тромбоэтина, фармацевтическая композиция и способ лечения
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US6251864B1 (en) 1995-06-07 2001-06-26 Glaxo Group Limited Peptides and compounds that bind to a receptor
US7091311B2 (en) 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
US7083983B2 (en) * 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
ES2284217T3 (es) 1997-10-31 2007-11-01 Smithkline Beecham Corporation Complejos metalicos novedosos.
DE69839191T2 (de) 1997-10-31 2009-02-19 Smithkline Beecham Corp. Metall-komplexe mit antibakteriele und fungizide wirkungen
EP1032388A4 (en) * 1997-10-31 2002-10-02 Smithkline Beecham Corp NEW METAL COMPLEXES
US7153655B2 (en) 1998-06-16 2006-12-26 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
TWI250988B (en) 1998-10-23 2006-03-11 Kirin Amgen Inc Thrombopoietic compounds
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
EP1216037A2 (en) * 1999-09-21 2002-06-26 Emory University Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents
US7668658B2 (en) 1999-10-13 2010-02-23 Sequenom, Inc. Methods for generating databases and databases for identifying polymorphic genetic markers
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
IL149340A0 (en) 1999-11-18 2002-11-10 Corvas Int Inc Nucleic acids encoding endotheliases, endotheliases and uses thereof
TWI284639B (en) * 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
CA2407956A1 (en) * 2000-05-03 2001-11-08 Amgen Inc. Modified peptides as therapeutic agents
US20050158838A1 (en) * 2000-06-19 2005-07-21 Dyax Corp., A Delaware Corporation Novel enterokinase cleavage sequences
US7396917B2 (en) 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US20040253242A1 (en) * 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
ATE320450T1 (de) * 2000-12-05 2006-04-15 Alexion Pharma Inc Rationell entworfene antikörper
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
AU2002305052A1 (en) 2001-03-13 2002-09-24 Corvas International, Inc. Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
AU2002254357A1 (en) 2001-03-22 2002-10-08 Dendreon Corporation Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon
WO2002077267A2 (en) 2001-03-27 2002-10-03 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembran serine protease 9, the encoded polypeptides and methods based thereon
CA2447050A1 (en) 2001-05-14 2002-11-21 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
US7332474B2 (en) * 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
WO2003044179A2 (en) * 2001-11-20 2003-05-30 Dendreon San Diego Llc Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
WO2003093296A2 (en) 2002-05-03 2003-11-13 Sequenom, Inc. Kinase anchor protein muteins, peptides thereof, and related methods
WO2003097834A2 (en) 2002-05-17 2003-11-27 Alligator Bioscience Ab A method for in vitro molecular evolution of protein function
AU2002328824A1 (en) * 2002-06-29 2004-01-19 Aquanova German Solubilisate Technologies (Agt) Gmbh Isoflavone concentrate and method for production thereof
US20040028661A1 (en) * 2002-08-07 2004-02-12 Bartelmez Stephen H. Expansion of cells using thrombopoietin and anti-transforming growth factor-beta
JP4412173B2 (ja) 2002-08-14 2010-02-10 日産化学工業株式会社 トロンボポエチンレセプター活性化剤ならびにそれらの製造方法
US7598224B2 (en) * 2002-08-20 2009-10-06 Biosurface Engineering Technologies, Inc. Dual chain synthetic heparin-binding growth factor analogs
US7166574B2 (en) 2002-08-20 2007-01-23 Biosurface Engineering Technologies, Inc. Synthetic heparin-binding growth factor analogs
US8227411B2 (en) * 2002-08-20 2012-07-24 BioSurface Engineering Technologies, Incle FGF growth factor analogs
EP1542714B1 (en) * 2002-09-18 2014-04-02 Ortho-McNeil Pharmaceutical, Inc. Methods of increasing platelet and hematopoietic stem cell production
TWI324593B (en) 2002-10-09 2010-05-11 Nissan Chemical Ind Ltd Pyrazolone compounds and thrombopoietin receptor activator
US20040248798A1 (en) 2003-02-14 2004-12-09 Peter Sutovsky Contraceptive methods and compositions related to proteasomal interference
BRPI0411172A (pt) * 2003-05-12 2006-07-18 Affymax Inc peptìdeo, dìmero de peptìdeo, seu uso e composição farmacêutica
JP2007500218A (ja) * 2003-05-12 2007-01-11 アフィーマックス・インコーポレイテッド ポリ（エチレングリコール）修飾ペプチド系化合物の新規スペーサー部分
DE602004028725D1 (de) * 2003-05-12 2010-09-30 Affymax Inc Neue poly(ethylenglycol) modifizierte erythropoietinagonisten und deren verwendungen
CN100441595C (zh) * 2003-05-12 2008-12-10 阿费麦克斯公司 结合红细胞生成素受体的新肽
CN1863783A (zh) * 2003-08-12 2006-11-15 盐野义制药株式会社 具有血小板生成素受体激动作用的化合物
US7723295B2 (en) * 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
ES2626107T3 (es) * 2003-08-28 2017-07-24 Janssen Pharmaceuticals, Inc. Péptidos y compuestos que se unen al receptor de trombopoyetina
WO2005063791A2 (en) 2003-12-31 2005-07-14 F. Hoffmann-La Roche Ag Process for peptide synthesis using a reduced amount of deprotection agent
US7414028B1 (en) 2004-02-04 2008-08-19 Biosurface Engineering Technologies, Inc. Growth factor analogs
US20080227696A1 (en) * 2005-02-22 2008-09-18 Biosurface Engineering Technologies, Inc. Single branch heparin-binding growth factor analogs
US7528105B1 (en) 2004-02-10 2009-05-05 Biosurface Engineering Technologies Heterodimeric chain synthetic heparin-binding growth factor analogs
US7671012B2 (en) 2004-02-10 2010-03-02 Biosurface Engineering Technologies, Inc. Formulations and methods for delivery of growth factor analogs
US20060024347A1 (en) * 2004-02-10 2006-02-02 Biosurface Engineering Technologies, Inc. Bioactive peptide coatings
WO2005082005A2 (en) 2004-02-20 2005-09-09 Biosurface Engineering Technologies, Inc., Et Al. Positive modulator of bone morphogenic protein-2
MX2007000216A (es) * 2004-07-08 2007-03-15 Amgen Inc Peptidos terapeuticos.
US20060210542A1 (en) * 2004-08-16 2006-09-21 Yurkow Edward J Use of TPO mimetic compounds and pharmaceutical compositions in the treatment of anemia
EP1797127B1 (en) 2004-09-24 2017-06-14 Amgen Inc. Modified fc molecules
US7589063B2 (en) 2004-12-14 2009-09-15 Aplagen Gmbh Molecules which promote hematopoiesis
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
WO2006060148A2 (en) * 2004-11-11 2006-06-08 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
AU2005312585B2 (en) 2004-12-08 2012-01-12 Nissan Chemical Industries, Ltd. 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators
RU2401259C2 (ru) 2004-12-14 2010-10-10 Ниссан Кемикал Индастриз, ЛТД Амидные соединения и активаторы рецептора тромбопоэтина
CA2600749C (en) 2005-03-10 2014-04-15 Nascacell Ip Gmbh Dimeric or multimeric microproteins
WO2006094530A1 (en) * 2005-03-11 2006-09-14 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
US7550433B2 (en) * 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
WO2006136450A2 (en) * 2005-06-23 2006-12-28 Aplagen Gmbh Supravalent compounds
TWI368617B (en) 2005-07-15 2012-07-21 Nissan Chemical Ind Ltd Thiophene compounds and thrombopoietin receptor activators
JP5104752B2 (ja) 2005-07-20 2012-12-19 日産化学工業株式会社 ピラゾール化合物及びトロンボポエチンレセプター活性化剤
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
EP1947101A4 (en) 2005-11-07 2009-09-16 Nissan Chemical Ind Ltd HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR
US7879318B2 (en) 2006-01-23 2011-02-01 Mcw Research Foundation, Inc. Method of reducing the effects of ischemia by administration of a thrombopoietin receptor ligand
WO2007102946A2 (en) 2006-01-23 2007-09-13 Amgen Inc. Crystalline polypeptides
WO2007087428A2 (en) * 2006-01-25 2007-08-02 Amgen Inc. Thrombopoietic compounds
EP1834963A1 (en) * 2006-03-13 2007-09-19 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
EP2005185B1 (en) * 2006-03-22 2010-10-20 Viral Logic Systems Technology Corp. Methods for identifying polypeptide targets
JO3324B1 (ar) 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
CA2652570A1 (en) * 2006-05-15 2007-11-22 Viral Logic Systems Technology Corp. Cd47 related compositions and methods for treating immunological diseases and disorders
US8377448B2 (en) * 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
US7820172B1 (en) 2006-06-01 2010-10-26 Biosurface Engineering Technologies, Inc. Laminin-derived multi-domain peptides
JP5157900B2 (ja) 2006-06-07 2013-03-06 日産化学工業株式会社 含窒素ヘテロ環化合物及びトロンボポエチンレセプター活性化剤
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
EP2046350A4 (en) 2006-06-22 2011-09-14 Biosurface Eng Tech Inc COMPOSITION AND METHOD FOR DELIVERING AMPLIFIER / CO-ACTIVATOR OF BMP-2 TO ENHANCE OSTEOGENESIS
WO2008051383A2 (en) * 2006-10-19 2008-05-02 Amgen Inc. Use of alcohol co-solvents to improve pegylation reaction yields
US8106154B2 (en) * 2007-01-31 2012-01-31 Affymax, Inc. Nitrogen-based linkers for attaching modifying groups to polypeptides and other macromolecules
EP2738257A1 (en) 2007-05-22 2014-06-04 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
WO2008157824A2 (en) * 2007-06-21 2008-12-24 Conjuchem Biotechnologies Inc. Thrombopoietin peptide conjugates
WO2009029682A1 (en) * 2007-08-28 2009-03-05 Rigel Pharmaceuticals, Inc. Combination therapy with syk kinase inhibitor
US8183342B2 (en) * 2007-11-06 2012-05-22 Case Western Reserve University Method of treating chemotherapy-induced thrombocytopenia
CN101481352A (zh) 2008-01-10 2009-07-15 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用
ES2500066T3 (es) 2008-01-25 2014-09-30 Amgen, Inc Anticuerpos frente a ferroportina y métodos de uso
MX2010011717A (es) 2008-05-01 2010-11-30 Amgen Inc Anticuerpos anti-hepcidina y metodos de uso.
US8734796B2 (en) 2009-03-20 2014-05-27 Amgen Inc. Carrier immunoglobulins
WO2011012306A2 (en) 2009-07-30 2011-02-03 Aplagen Gmbh Use of emps for antagonising epo-stimulatory effects on epo-responsive tumors while maintaining erythropoiesis
JP5704073B2 (ja) 2009-10-23 2015-04-22 日産化学工業株式会社 縮環へテロ環化合物及びトロンボポエチンレセプター活性化剤
WO2011098095A1 (en) 2010-02-09 2011-08-18 Aplagen Gmbh Peptides binding the tpo receptor
EA201370076A1 (ru) 2010-09-22 2013-08-30 Амген Инк. Иммуноглобулины-переносчики и их применение
WO2014159242A1 (en) 2013-03-14 2014-10-02 Novartis Ag Notch 3 mutants and uses thereof
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
CA2960778C (en) 2014-09-11 2023-03-07 Bristol-Myers Squibb Company Macrocyclic inhibitors of the pd-1/pd-l1 and cd80(b7-1)/pd-l1 protein/protein interactions
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
WO2016079219A1 (en) 2014-11-19 2016-05-26 Koninklijke Philips N.V. Diagnostic method employing hnl
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
EA038019B1 (ru) 2016-05-19 2021-06-23 Бристол-Маерс Сквибб Компани Иммуномодуляторы для пэт-визуализации
CN110267971B (zh) 2016-11-07 2023-12-19 百时美施贵宝公司 免疫调节剂
EP3642220A1 (en) 2017-06-23 2020-04-29 Bristol-Myers Squibb Company Immunomodulators acting as antagonists of pd-1
AU2018306329B8 (en) * 2017-07-26 2025-02-20 Janssen Pharmaceutica Nv Methods of protecting vascular integrity induced by targeted radiation therapy
WO2019070643A1 (en) 2017-10-03 2019-04-11 Bristol-Myers Squibb Company IMMUNOMODULATORS
JP7664163B2 (ja) 2019-01-25 2025-04-17 ヤンセン ファーマシューティカ エヌ．ベー． 全身照射／化学曝露に対する応答において臓器および血管損傷、造血回復ならびに生存に対する保護を増強する方法
EP3914272B1 (en) * 2019-01-25 2024-03-06 Janssen Pharmaceutica NV Thrombopoietin mimetics for mitigating liver injury and promoting liver hypertrophy, regeneration and cell engraftment in conjunction with radiation and/or radiomimetic treatments
EP3914286B1 (en) 2019-01-25 2025-05-07 Janssen Pharmaceutica NV Methods of mitigating toxic effects of vesicants and caustic gas
WO2021141684A1 (en) 2020-01-06 2021-07-15 Bristol-Myers Squibb Company Immunomodulators
IL311797A (en) 2021-10-01 2024-05-01 Albert Einstein College Medicine Methods of increasing progenitor cell production
WO2024095178A1 (en) 2022-11-01 2024-05-10 Janssen Pharmaceutica Nv Thrombopoietin mimetic for use in the treatment of acute liver failure

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2046920B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1969-06-19 1974-05-03 Citizen Watch Co Ltd
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4612132A (en) 1984-07-20 1986-09-16 Chevron Research Company Modified succinimides
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5198424A (en) * 1989-03-08 1993-03-30 Board Of Regents Of The University Of Oklahoma Functionally active selectin-derived peptides
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5326558A (en) * 1989-08-08 1994-07-05 Genetics Institute, Inc. Megakaryocytopoietic factor
IL96477A0 (en) * 1989-12-01 1991-08-16 Amgen Inc Megakaryocyte production
US5571508A (en) * 1989-12-18 1996-11-05 Amrad Corporation Limited Method for the treatment of thrombocytopenia and pharmaceutical compositions useful therefor
IT1241395B (it) * 1990-04-02 1994-01-10 Eniricerche Spa Composti immunogenici,il procedimento per la loro sintesi e loro impiego per la preparazione di vaccini antimalaria
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5250732A (en) * 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
DE69332222T3 (de) * 1992-06-11 2007-05-10 Alkermes Controlled Therapeutics, Inc., Cambridge Enythropoietin enthaltendes arzneimittelabgabesystem
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
AU685506B2 (en) 1993-08-25 1998-01-22 Systemix, Inc. Method for producing a highly enriched population of hematopoietic stem cells
AU8124694A (en) * 1993-10-29 1995-05-22 Affymax Technologies N.V. In vitro peptide and antibody display libraries
SG47030A1 (en) * 1994-01-03 1998-03-20 Genentech Inc Thrombopoietin
SG79882A1 (en) * 1994-02-14 2001-04-17 Kirin Brewery Protein having tpo activity
CA2169173C (en) * 1994-02-14 2002-10-15 Kenneth Kaushansky Methods for stimulating erythropoiesis using thrombopoietin
KR100289201B1 (ko) * 1994-02-14 2001-05-02 엘. 데이예를 카렌. 조혈 단백질과 그것의 제조를 위한 재료 및 방법
WO1995021919A2 (en) * 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
US5766581A (en) * 1994-03-31 1998-06-16 Amgen Inc. Method for treating mammals with monopegylated proteins that stimulates megakaryocyte growth and differentiation
US5571686A (en) * 1994-04-14 1996-11-05 Massachusetts Institute Of Technology Method of using megapoietin for prolonging the survival & viability of platlets
AU4163196A (en) * 1994-11-30 1996-06-19 Zymogenetics Inc. Low molecular weight thrombopoietin
US5641655A (en) * 1994-11-30 1997-06-24 Zymogenetics, Inc. Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
AU705064B2 (en) * 1995-04-26 1999-05-13 Kyowa Hakko Kogyo Co. Ltd. Novel polypeptides
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
EA001220B1 (ru) 1995-06-07 2000-12-25 Глаксо Груп Лимитед Пептид или пептидомиметик, который связывается с рецептором тромбоэтина, фармацевтическая композиция и способ лечения
KR102127408B1 (ko) 2014-01-29 2020-06-29 삼성전자주식회사 항 Her3 scFv 단편 및 이를 포함하는 항 c-Met/항 Her3 이중 특이 항체

Also Published As

Publication number Publication date
DE69739219D1 (de) 2009-03-05
CN1245504A (zh) 2000-02-23
TNSN97201A1 (fr) 2005-03-15
KR100679576B1 (ko) 2007-02-07
ZA9711045B (en) 1999-06-09
TR199901971T2 (xx) 1999-12-21
JP2001505898A (ja) 2001-05-08
CA2274149A1 (en) 1998-06-18
EP0948539A2 (en) 1999-10-13
BRPI9713914B1 (pt) 2017-06-20
MA26454A1 (fr) 2004-12-20
JP4128225B2 (ja) 2008-07-30
PA8442601A1 (es) 2000-05-24
BR9713914A (pt) 2000-02-29
CN100379760C (zh) 2008-04-09
WO1998025965A2 (en) 1998-06-18
US5869451A (en) 1999-02-09
AU5854798A (en) 1998-07-03
CO5080768A1 (es) 2001-09-25
TW515804B (en) 2003-01-01
ES2321038T3 (es) 2009-06-01
HRP970683A2 (en) 1998-10-31
US6121238A (en) 2000-09-19
AU725731B2 (en) 2000-10-19
SV1997000104A (es) 1998-09-18
TR200401638T2 (tr) 2004-11-22
AR010752A1 (es) 2000-07-12
KR100625708B1 (ko) 2006-09-20
ATE420893T1 (de) 2009-01-15
WO1998025965A3 (en) 1998-08-13
EP2028191A1 (en) 2009-02-25
KR20050042505A (ko) 2005-05-09
KR100668546B1 (ko) 2007-01-16
EP0948539B1 (en) 2009-01-14
AR062931A2 (es) 2008-12-17
HRP970683B1 (en) 2002-10-31
PE27599A1 (es) 1999-03-29
KR20060025611A (ko) 2006-03-21
BRPI9713914B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2021-05-25
CA2274149C (en) 2008-07-15
EP2336165A1 (en) 2011-06-22
KR20000069408A (ko) 2000-11-25

Similar Documents

Publication Publication Date Title
UY24805A1 (es) Peptidos y compuestos que se enlazan al receptor de la trombopoyetina
GT199800158AA (es) Agonistas de prostaglandinas y su uso para tratar trastornos oseos
ES2191152T3 (es) Terapia combinada para el tratamiento de psicosis.
HN1999000080A (es) Derivados de isotiazol utiles como agentes anticancerosos.
BR0317747A (pt) Método de tratamento terapêutico concomitante de um indivìduo, composição farmacêutica, kit, uso de um primeiro agente e um segundo agente, e, métodos de prevenir ou tratar uma doença relacionada com amilóide-b, doença de alzheimer e insuficiência cognitiva suave
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
PA8462401A1 (es) Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos
AR005987A1 (es) Terapia combinada para la osteoporosis
BG104247A (en) Resorcinol derivatives
GT199700079A (es) Derivados triciclos sustituidos con fenilamino
ES2105707T3 (es) Agentes que contienen isatina para el teñido de fibras que contienen queratina.
ES2179351T3 (es) Amidas acidas de piridil alqueno y piridil alquino como citoestaticos e inmunosupresores.
ECSP055609A (es) "Uso de inhibidores de la IkB-quinasa para el tratamiento del dolor"
PA8452701A1 (es) Agonistas de prostaglandinas
ES2184970T3 (es) Utilizacion de derivados de la melatonina para la despigmentacion de la piel y composiciones que las comprenden.
EE9900036A (et) Uued ühendid ja kompositsioonid trüptaasi aktiivsusega seotud haiguste raviks
AR003589A1 (es) Utilizacion de una cantidad eficaz de al menos un peptido en una composicion cosmetica o para la preparacion de un medicamento destinada paratratar la inflamacion, y un procedimiento de tratamiento cosmetico mediante una composicion cosmetica que contiene a dicho peptido.
ES2169420T3 (es) Compuestos triciclicos utiles para inhibir la funcion de la proteina g y para tratar enfermedades proliferativas.
DE69918972D1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
BR0009211A (pt) Derivados de resorcinol
DK0417003T3 (da) Anvendelse af antiprogestomimetiske forbindelser til fremme af ovulation
ES2174196T3 (es) Utilizacion de ceramida para el tratamiento de las uñas.
ES2102284T3 (es) Composicion cosmetica que comprende una asociacion de ceramidas y su utilizacion.
PT928197E (pt) Utilizacao de proteinas como agentes contra doencas de natureza autoimunitaria
ECSP003590A (es) Compuestos calcioliticos

Legal Events

Date Code Title Description
VENC Patent expired

Effective date: 20171210